Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUVAMER: Hydroxyurea or 6-MP with Valproic Acid in Unfit AML/HR-MDS
NCT06199557Phase 2Recruiting
- Sponsor
- Haukeland University Hospital
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valproic acid in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Haukeland University Hospital. Started May 2024; status: recruiting.
02
Drugs
valproic acid
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06199557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199557.